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b s t r a c t
Aromatase Inhibitors (AI) are widely used for the adjuvant treatment of hormone receptor positive breast cancers in the post-menopausal population. AI are often associated with significant joint and muscular symptoms; symptoms that are commonly referred to as aromatase inhibitor-associated musculoskeletal syndrome (AIMSS). AIMSS adversely impacts health-related quality of life of many patients, and reduces AI compliance. Although there are informal practice recommendations, the limited current level of evidence for management of AIMSS for breast cancer patients on aromatase inhibitors has made development of formal guidelines challenging, and remains an unmet need. This is the first systematic review to consider the evidence for all pharmacological and non-pharmacological interventions in the treatment of AIMSS, including physical therapy, acupuncture and complementary therapies.
© 2017 Elsevier B.V. All rights reserved.
Introduction
Aromatase Inhibitors (AI) are recommended for the adjuvant treatment of hormone receptor positive breast cancers in the post-menopausal population. These agents block the synthesis of oestrogen by inhibition of peripheral aromatase (Miller et al., 2003) . Compared with Tamoxifen, third generation aromatase inhibitors have been shown to significantly improve disease free survival (DFS) (Cuzick et al., 2010; Regan et al., 2011; Ingle et al., 2006) , and include the steroidal inhibitor exemestane, and the nonsteroidal inhibitors, anastrozole and letrozole. In the 2013 meta-analysis by Aydiner et al. (Aydiner, 2013) , five years of adjuvant therapy with aromatase inhibitors improved DFS (HR 0.89, p = 0.001), and also overall survival (OS) (HR 0.92, p = 0.046) when compared to tamoxifen. Aromatase inhibitors have also demonstrated improvement in DFS, OS and distant metastasis rate when sequenced with tamoxifen (HR 0.70, p < 0.001; HR 0.81, p = 0.003, HR 0.74, p < 0.001 respectively), and an improvement in DFS as extended adjuvant treatment after 5 years of tamoxifen (HR 0.62, p = 0.001) (Aydiner, 2013) . Recent evidence has revealed a benefit of continuing aromatase inhibitors for a period of 10 years, as reported in the MA.17R trial, which displayed significant improvement in breast cancer recurrence rates, and decreased contralateral breast cancer (Goss et al., 2016) .
Aromatase inhibitors are associated with joint and muscular symptoms, commonly referred to as aromatase inhibitorassociated musculoskeletal syndrome (AIMSS) (Lintermans et al., 2013) . AIMSS adversely impacts on the quality of life of many patients. Studies recently investigating AIMSS have shown incidence of musculoskeletal symptoms to be as much as 50% (Coleman et al., 2008; Laroche et al., 2014; Menas et al., 2012) , higher than the pivotal aromatase inhibitor trials with rates of approximately 20-35% (Muss et al., 2008; Coates et al., 2007; Howell et al., 2005) . The prevalence of musculoskeletal symptoms impacts the longterm care of these patients. Analysis of longitudinal claims data from three American commercial health programs revealed suboptimal adherence to anastrozole in 19-28% of patients in their first year of treatment (Partridge et al., 2008) . These statistics are consistent with other studies of aromatase inhibitor adherence (Hadji et al., 2014; Hershman et al., 2011; Presant et al., 2007; Henry et al., 2012) , which report a significant percentage of patients displaying early discontinuation of treatment. There are important clinical implications of this data, as non-compliance with adjuvant endocrine therapies in early breast cancer has been shown to be detrimental to the patients' survival (Hershman et al., 2011) .
AIMSS usually presents as symmetrical pain or soreness in the hands, knees, hips, lower back, shoulders, and/or feet. It is often associated with early-morning stiffness and difficulty sleeping (Burstein, 2007) . There may be additional extra-articular symptoms present, such as myalgia, fibromyalgia, neuropathy and carpal tunnel syndrome (Sestak et al., 2009 ). MRI studies conducted on patients taking aromatase inhibitors have shown the development of tenosynovial changes and increased intra-articular fluid in patients with AIMSS (Lintermans et al., 2013) . Most of the symptoms will develop within the first two to three months of AI treatment (Burstein, 2007; Mao et al., 2009a) . This systematic review aims to summarise the recent literature on the symptom management intervention strategies for AIMSS. Meta-analyses have been conducted where feasible.
Methods
Search strategy
A systematic search of the electronic literature was designed and conducted by an information specialist (KR) to identify the relevant evidence. The following databases were searched: PubMed, EMBASE, CINAHL and CENTRAL. Controlled terminology (MESH, EMTREE, CINAHL headings) and free text words were used. Google scholar was also searched for unpublished literature. The final search of all the databases was conducted on 24th February 2016. Reference lists of relevant review articles and of the full text reviewed papers were also cross checked and any relevant papers included for review. The complete search strategies for all the databases can be found in Appendix A.
Study selection: inclusion and exclusion criteria 2.2.1. Type of studies
Although the best type of study to assess the efficacy of an intervention is a randomised controlled trial (RCT), the scope of studies for inclusion in this review has been expanded. This is to reflect the recognition that there are very few RCT in the area, and to be inclusive of as many intervention types as possible to inform clinical practice and respond to patient enquiries. Therefore, all clinical trials (prospective and retrospective), cohort and case control studies and preventative trials were considered. Conference abstracts were included, but where a later full paper has been published, the abstract was excluded and replaced with the full paper. Letters to the editor detailing clinical trial results were also included. Conference abstracts and letters to the editor were only considered in the narrative analysis and were not included in the risk of bias assessment or meta-analysis as there was not enough infor-mation to make an accurate analysis. Case studies and small case series were excluded. Papers detailing protocols only, as well as systematic reviews were excluded from the review, although these are considered in the discussion. Only papers published in English were considered.
Types of participants
Women with stage I-III Breast Cancer on an adjuvant treatment with any aromatase inhibitor with, or at risk of, AIMSS were included. AIMSS was defined as any new onset, or worsening, of any musculoskeletal symptom after commencement of an AI. Women with advanced/metastatic breast cancer (Stage IV) were excluded. Papers which did not clearly define the use of aromatase inhibitors distinct to other hormonal therapies were excluded, along with papers which included endocrine therapies other than aromatase inhibitors
Types of intervention
All types of symptom management interventions for AIMSS in this population were considered including -pharmacological, non-pharmacological and CAM (Complementary and Alternative Medicine).
Types of outcome measures
Primary outcomes and secondary outcomes included the improvement in AIMSS (pain, stiffness, mobility or functionality) from baseline, the improvement in persistence and compliance of patients continuing to take their aromatase inhibitor medication due to the intervention, the reduction in incidence of AIMSS, and the adverse events in relation to the intervention treating AIMSS symptoms.
Data synthesis and analysis
Where sufficient quantitative results were reported, metaanalysis was performed. I 2 was used to measure heterogeneity between studies, as per the Cochrane handbook (Cochrane Handbook, 2011 ). An I 2 value of 50-75% is defined as substantial heterogeneity and an I 2 value of ≥75% is defined as considerable heterogeneity. Heterogeneity was expected between studies, and therefore a random-effects meta-analysis model was used for the meta-analyses. A separate meta-analysis was attempted for each sub-group of intervention. R programming software was used for the statistical analysis (Schwarzer , 2016) .
Methodological quality
RCTs were assessed using the Jadad Scale (Olivo et al., 2008) . Trials were deemed high quality studies if score 3-5, whilst score 0-2 was deemed low quality (Jadad et al., 1996) . Case control studies were assessed using the Newcastle-Ottawa Scale, where a score of 7-9 indicates high methodological quality, a score of 4-6 indicates moderate quality and a score of 0-3 indicates low quality.
Results
Search results
The search retrieved 1389 articles and after the removal of 458 duplicates, 931 remaining abstracts were screened, as shown in Fig. 1 . After 836 of these abstracts were excluded, 95 full text articles were assessed, with 38 meeting the inclusion criteria. 57 papers were excluded: In 17 studies the relevant outcomes were not covered; in 12 studies hormonal therapy was not distinguished as AI; in 11 studies the abstracts were superseded by later full text papers; 10 papers were the wrong study design or publication type; 6 papers had the wrong patient setting; and 1 paper was not in English.
Methodological quality of selected studies
Studies were unable to be assessed if they had only been published as an abstract, due to lack of available information. Out of 17 RCTs, only 11 could be adequately assessed for methodological quality, as the rest were only published in abstract form. Of the 11 assessable RCTs, eight studies had a high Jadad score ≥3 (Shapiro et al., 2016; Rastelli et al., 2011; Oh et al., 2013; Mao et al., 2014; Hershman et al., 2015; Crew et al., 2010; Bao et al., 2013; Fields, 2015) . Three studies scored poorly on the Jadad scale for methodological quality (Crew et al., 2007; Irwin et al., 2015; Liu et al., 2014) . Only six cohort studies had fulltext available for assessment with the Newcastle Ottowa Scale. Of these six studies, two were assessed as high methodological quality (Prieto-Alhambra et al., 2011; Cantarero-Villanueva et al., 2013) ; two studies were median methodological quality (Presant et al., 2007; Khan et al., 2010; Muslimani et al., 2009) ; and one study was of poor methodological quality (Xepapadakis et al., 2010) .
Overall characteristics of selected studies
38 studies were included in the final analysis (see Table 1 ). These included 18 randomised control trials (RCTs)/controlled clinical trials (CCT), 14 pre/post studies, and 6 cohort studies. Studies were published between 2007 and 2016. The countries in which the studies were conducted include: United States (n = 26), Japan (n = 2), Spain (n = 2), China (n = 2), Canada (n = 1), England (n = 1), Australia (n = 1), Greece (n = 1), France (n = 1) and Italy (n = 1). Of the trials which reported median ages of participants, the median age was 59.5 years (range 29-89). The scoring systems used across trials were extremely diverse, including Health Assessment Questionnaire (HAQ) The studies were analysed in four separate subgroups: Complementary Therapies; Acupuncture; Physical Therapies and Pharmacological Interventions.
Analysis of acupuncture interventions
Study characteristics
Six studies were included that investigated the use of acupuncture for AIMSS, involving 221 patients in total. There were five RCTs, three of which investigated the use of acupuncture (Crew et al., 2010; Bao et al., 2013; Crew et al., 2007) and two of which investigated the use of electro-acupuncture (Oh et al., 2013; Mao et al., 2014) . There was also one single-arm pilot study, which investigated the use of electroacupuncture (Mao et al., 2009b) . Of the RCTs, three studies investigated true acupuncture/electro-acupuncture No difference between groups in regards to pain at 4 or 6 months. versus sham acupuncture (Oh et al., 2013; Crew et al., 2010; Bao et al., 2013) ; one study had three arms consisting of true electroacupuncture, sham electro-acupuncture and a waitlist control (Mao et al., 2014) and one trial was a crossover design, investigating acupuncture versus observation, then crossover after six weeks (Crew et al., 2007) . The methods of sham acupuncture differed between trials, with some trials using sham, non-penetrating needles on real acupuncture points (Oh et al., 2013) , and others using sham, non-penetrating needles at non-acupuncture, non-trigger points (Mao et al., 2014; Bao et al., 2013) . Crew et al. (Crew et al., 2010) , used superficial needle insertion at non-acupuncture points as the control. The median sample size for the studies was 37 (range 12-67). The primary outcome of all the studies included change in pain scores after the intervention. One study also listed primary outcomes as perceived benefit of acupuncture, hand strength and inflammatory markers (ESR and CRP) (Oh et al., 2013) .
Results
In the two RCTs by Crew et al. (2010 Crew et al. ( , 2007 , there was a reported benefit in the symptoms of AIMSS with the use of acupuncture. In the 2007 trial of 21 patients (Crew et al., 2007) , patients underwent six weeks of acupuncture followed by six weeks of observation, or vice versa. The mean BPI worst pain score at baseline was 5.3 compared with the mean BPI worst pain score after acupuncture of 3.3 (p = 0.008). The benefits of acupuncture did not persist after six weeks of observation. In the 2010 RCT by Crew et al. (2010) , 43 patients were randomised to either real or sham acupuncture for six weeks. There was a difference in pain scores at six weeks between true acupuncture and sham acupuncture arms, with mean BPI-SF worst pain scores 3.0 for true acupuncture versus 5.5 for sham acupuncture (p = 0.002). Similar benefits were seen in pain severity (2.59v 4.53; p < 0.001) and pain-related interference (2.48v 4.54; p < 0.002). No follow-up was performed after acupuncture cessa- tion. In all the remaining RCTs investigating the use of acupuncture there was no statistical difference in pain outcomes between real and sham arms (Oh et al., 2013; Mao et al., 2014; Bao et al., 2013) . In the trial by Bao et al. (2013) , 47 patients were randomised to real or sham acupuncture for eight weeks. After eight weeks, there was no difference between treatment arms in either HAZ-DI scores (p = 0.15) or VAS scores (p = 0.31). Oh et al. (2013) , investigated real versus sham electroacupuncture for six weeks of treatment in 32 patients. There was no difference between real and sham arms in regards to pain, function and stiffness using WOMAC scores, or pain severity and interference using BPI-SF scores. In the trial by Mao et al. (2014) , 67 patients were enrolled into a three arm RCT, investigating real and sham electroacupuncture versus a waitlist control arm, for eight weeks. Both true electroacupuncture (EA) and sham electroacupuncture (SA) arms revealed a significant improvement in pain severity compared with the waitlist control arm (−2.0 vs −0.2, p = 0.0004), but there was no difference between EA and SA arms.
Two studies could be included in the method of meta-analysis, as they used the same scoring systems within their studies (Mao et al., 2014; Crew et al., 2010) (Fig. 2) . There was significant betweenstudy heterogeneity for the effects of acupuncture on BPI-SF worst pain score (I 2 = 79%). The overall mean difference in worst pain scores after acupuncture, using the random effects model was −0.98 (95% CI, −;3.01-1.06).
Analysis of pharmacological interventions
Study characteristics
Twelve studies were included that investigated pharmacological interventions for the management of AIMSS, including 3 RCTs, 5 pre/post studies, and 4 cohort studies. Pharmacological ther- apies used were diverse, and included testosterone (Birrell and Tilley, 2010) , etoricoxib (Rosati et al., 2011) , calcitonin (Liu et al., 2014) , duloxetine (Henry et al., 2011) , prednisolone (Kubo et al., 2012) , thymosin (Zhang et al., 2010) , bisphosphonates (Muslimani et al., 2009; Santa-Maria et al., 2014) , diuretics (Xepapadakis et al., 2010) and switching of aromatase inhibitor therapy (Kadakia et al., 2016; Briot et al., 2010) . There were 1407 patients analysed in total between all the pharmacological trials, with a median sample size of 82.5 patients (range 16-316). The RCTs used a matched placebo in the control arms, and one of the retrospective cohort studies used controls from the ELPh Trial (Exemestane and Letrozole Pharmacogenetics Trial) (Santa-Maria et al., 2014) . The other studies did not include a control arm. The primary outcome for majority of the studies was either the impact of the pharmacological intervention on musculoskeletal symptoms, or the prevention of musculoskeletal symptoms through use of the pharmacological intervention. The study by Liu et al., had a primary outcome of the efficacy of calcitonin as therapy for osteoporosis in patients with bone pain during anastrozole therapy (Liu et al., 2014) . In the study of switch therapy by Briot et al. (2010) , the primary outcome was the percentage of women who discontinued letrozole secondary to musculoskeletal symptoms, after switching from anastrozole. Likewise, in the study of switch therapy by Kadakia et al., the primary outcome was tolerance of, and persistence with aromatase inhibitors (Kadakia et al., 2016) . In the study of etoricoxib (Rosati et al., 2011) , the primary end-point was 5 years event free survival.
Results
Patients in all three RCTs experienced a reduction in pain, which was the primary outcome (Liu et al., 2014; Birrell and Tilley, 2010; Rosati et al., 2011) . In the trial by Birrell and Tilley (2010) , which has only been published as an abstract, 80 mg testosterone resulted in a 70% decrease in Visual Analogue Scores (VAS) scores at 3 months, compared to only 35% decrease in VAS scores in the placebo arm (p = 0.04). The third arm in this trial, testing 40 mg testosterone, did not result in a substantial decrease in pain scores (p = 0.06). The use of testosterone was not associated with a significant elevation in serum oestradiol. Rosati et al. studied the use of etoricoxib (60 mg/day) versus placebo, in addition to anastrozole (Rosati et al., 2011) . This study has also only been published as an abstract. During the trial, there was a U.S. Food and Drug Administration (FDA) alert on the use of etoricoxib and the potential risk for cardiovascular toxicity, resulting in a 38% discontinuation rate. Despite this, the incidence of musculoskeletal pain was still significantly higher in the placebo arm (RR 2.1, 95% CI 1.29-3.43, p = 0.002). The third RCT, by Liu et al. investigated calcitonin 200 IU/day plus caltrate D 600 mg/day versus caltrate D alone for a period of three months (Liu et al., 2014 ). An improvement in pain scores, measured by VAS, was identified in both the placebo arm (score difference −1.00, p = 0.0013) and intervention arm (score difference &−3.00, p < 0.0001). There was also notably a difference between the improvement in pain scores between the two arms (p < 0.0001) (Liu et al., 2014) .
Analysis of complementary interventions
Study characteristics
Ten studies were included that investigated the use of complementary therapies, including 6 RCTs, 2 cohort studies and 2 pre/post studies. The interventions included Blue Citrus Herbal (Massimino et al., 2011) , omega-3-fatty-acids (O3FA) (Hershman et al., 2015; Lustberg et al., 2015) , vitamin D (Shapiro et al., 2016; Rastelli et al., 2011; Prieto-Alhambra et al., 2011; Khan et al., 2010; Khan et al., 2012) vitamin E (Kiyomi et al., 2015) and glucosamine/chondroitin (Greenlee et al., 2013) . The total number of patients investigated with complementary interventions was 403. The median sample size was 61 (range 31-209). All RCTs used a placebo as the comparator arm. The primary endpoint of majority of studies included the impact of the intervention on AIMSS. In the pilot study investigating O3FA, the primary outcome was feasibility (Lustberg et al. 2015) , but the secondary outcome included patient-reported outcomes (PRO) of AIMSS. In the pre/post study of vitamin E, the primary outcome was the effect of vitamin E administration on female hormones and cytokines in patients experiencing AIMSS (Kiyomi et al., 2015) . Secondary outcomes included the effects of vitamin E on severity of AIMSS. In the vitamin D RCTs, the dosing of vitamin D in the intervention arms varied between studies, with interventions including 4000IU/day vitamin D3 (Shapiro et al., 2016) ; 50,000IU vitamin D weekly (Rastelli et al., 2011) ; and 30,000 IU vitamin D3 weekly (Khan et al., 2012) .
Results
All three of the RCTs investigating the use of vitamin D (Shapiro et al., 2016; Rastelli et al., 2011; Khan et al., 2012) , showed no benefit in the use of vitamin D for the management of AIMSS. The RCT investigating the use of Blue Citrus Herbal (Massimino et al., 2011) , which included 37 patients in the study, reported improvement in VAS pain scores with the use of Blue Citrus Herbal, but it was unclear if these improvements were statistically significant compared to the control arm. Some Blue Citrus herbal formulations can include up to 15 different herbs, including Curcuma (Qi Herbal Apothecary, 2017). Caution is advised for usage of Curcuma in women with hormone sensitive conditions as theoretically it may exacerbate hormone sensitive breast, uterine or ovarian cancers (Natural Medicines Comprehensive Database, 2016) . The specific formulation of the herb used in this trial is unclear. The two RCTs investigating the use of O3FA (Hershman et al., 2015; Lustberg et al., 2015) did not find any benefit of O3FA when compared to placebo. The larger of the O3FA RCTs, comprising 249 patients (Hershman et al., 2015) , reported a substantial improvement in AIMSS at 12 weeks in both the O3FA arm (BPI-SF score change −1.74, p < 0.001) and the placebo arm (BPI-SF score change −1.50, p < 0.001), but no significant difference between groups (p = 0.38). These results were sustained at the 24 week evaluation. The only positive result in the smaller O3FA RCT (Lustberg et al., 2015) was greater pain relief from medications in the O3FA arm at both 12 weeks (p = 0.043) and 24 weeks (p = 0.011).
6.1. Analysis of physical therapy interventions 6.1.1. Characteristics of studies Ten studies were included that investigated the use of physical therapies on the management of AIMSS, including 3 RCTs, 6 pre/post studies and a CCT. Three studies investigated a combined aerobic and resistance exercise program, including two randomised control trials (Irwin et al., 2015; Lohrisch et al., 2011) , and one pre/post study (Lash et al., 2011) . One pre/post study investigated a home-based exercise program (DeNysschen et al., 2014) , and two studies investigated walking programs, including one RCT involving Nordic Walking (Fields, 2015) , and one pre/post study investigating a self-directed walking program (Nyrop et al., 2014) . One pre/post study investigated Tai Chi (Galantino et al., 2013) , and two other pre/post studies investigated yoga (Jacobsen et al., 2015; Galantino et al., 2012) . A CCT investigated aquatic exercise (Cantarero-Villanueva et al., 2013) . Therefore, the physical therapy interventions were extremely heterogeneous, ranging from two one hour tai chi sessions per week for 8 weeks (Galantino et al., 2013) , to 150 min of aerobic exercise weekly plus supervised strength training twice weekly (Irwin et al., 2015) . The mean sample size between studies was 31 patients (range 10-121). The total number of patients investigated in exercise trials was 313.
Of the 3 RCTs, there was only one study showing benefit with physical therapy (Irwin et al., 2015) . The HOPE study, by Irwin et al., was the largest of the exercise studies in our analysis, with 121 participants (Irwin et al., 2015) . The study reported a 29% improvement in worst BPI scores in the exercise group at 12 months, as compared to a 3% increase in worst pain scores in the usual care group at 12 months (p < 0.001) (Irwin et al., 2015) . The RCT by Fields investigating the use of Nordic walking versus waitlist control did not report any significant benefit in regards to AIMSS (Fields, 2015) . The RCT by Lohrisch et al. (Lohrisch et al., 2011) , closed early due to poor recruitment, and did not identify any significant benefit in the use of a mixed aerobic/resistance exercise program for the management of AIMSS.
Two studies could be included in a meta-analysis of physical therapy interventions, as only two studies had the same pain scoring system within their studies, with available results (Fields, 2015; Irwin et al., 2015) (Fig. 3) . There was significant between-study heterogeneity for the effects of physical therapy on BPI-SF worst pain score (I 2 = 93%). The overall mean difference in worst pain scores after exercise intervention, using the random effects model was −0.29 (95% CI, −3.32-2.75).
Discussion
With the improving long-term prognosis for breast cancer patients, there is an increasing focus on survivorship, and the quality of life for breast cancer survivors. Despite the burden of AIMSS in the treatment of hormone receptor positive breast cancer, there is a paucity of large, well-designed trials to provide evidence on the management of this condition. It should be emphasized that there is currently no standardised definition of AIMSS. The condition encompasses a broad range of symptoms, and therefore a standardised definition would not only assist trial design in the future, but also assist oncologists to recognise and manage this condition in the clinical setting.
In compiling this analysis, we identified a variety of factors which unfortunately compromise the quality of the available evidence. The majority of trials considered in this analysis included patients who either already experienced musculoskeletal symptoms which worsened after the initiation of an AI, or patients who developed new onset musculoskeletal symptoms after initiation of an AI. However, several trials which did not stipulate their inclusion requirement for AIMSS at entry. Poorly defined entry criteria may have resulted in some trials investigating long-standing musculoskeletal conditions, such as osteoarthritis, rather than AIMSS specifically. Furthermore, interventions with low perceived toxicity would be more likely to have uptake in patient groups with less severe symptoms leading to differences in patient groups between trials (Pavuluri et al., 2004) . The retrospective studies would have likely used physician-reported AIMSS and outcomes, whereas the most reliable process for reporting patient quality of life outcomes includes patient reported outcomes (PRO). (Deshpande et al., 2011) In the trials included in this analysis, a diverse range of scoring symptoms were used to record patient symptoms. Due to the heterogeneity of scoring systems used, it was difficult to compare the benefit of interventions between trials. The more simplistic scoring systems, such as VAS, may result in either overestimation or underestimation of the perceived benefit of an intervention. Multiple studies did not disclose their complete list of scoring results, which may indicate a risk of bias in the reporting of results.
Our analysis included many studies investigating the management of AIMSS, but overall they provide poor quality evidence in this area. The majority of studies had small sample sizes and a high risk of inherent bias. As expected, it is extremely difficult to blind the intervention group in certain studies, and impossible to blind treatment arms in the physical therapy groups. The placebo effect has been found to be significant in other studies of pharmacological treatment of debilitating toxicities of cancer treatment (Pavuluri et al., 2004; Smith et al., 2013; Spathis et al., 2014) . In addition, the choice of placebo or control arm may have contributed to some borderline results. Careful consideration should be given to the choice Fig. 3 . Effect of physical therapy on AIMSS using BPI-SF. SD, standard deviation; MD, mean difference; CI confidence interval.
of placebo, as contamination may be a problem. For example, in one trial investigating the use of O3FA (Hershman et al., 2015) , soybean was used in the placebo tablet. It has been hypothesised that an oestrogenic component in soy may have impacted on the pain scores in the control arm. In a number of acupuncture trials, there was an improvement in pain scores in both the real acupuncture and sham acupuncture arms. It is theorised that sham acupuncture may provide a therapeutic benefit by triggering the release of endorphins or activation of pain related neural matrix (Chien et al., 2015) . Many of the acupuncture trials have gone to great lengths to attempt to eliminate the risk of bias from their study, but as expected, they have not been able to successfully blind their treatment arms to patients. This may have resulted in a bias of results stemming from positive patient expectations. Most of the studies also did not report trial participants' usage of other medications, including analgesia. There should be rigorous control for medications taken by trial participants, to prevent confounding variables affecting the trial outcome.
There are a number of trials currently ongoing, with interventions such as duloxetine (NCT01598298), the interplay of pain, sleep quality and fatigue (NCT01983995), hypnosis (NCT02657993), testosterone (NCT01573442), acupuncture (NCT01535066), vitamin D (NCT01988090), and kinesiotaping (NCT02406794). Hopefully these trials will provide further evidence for the optimal management of AIMSS.
Conclusion
Suboptimal compliance with AI adjuvant therapy due to inadequately managed AIMSS remains a major unmet need in oncology practice. Patients who have failed to control AIMSS with over the counter analgesics may be willing to try other interventions, including complementary therapies, for symptom relief. Many of these women have been financially impacted by their cancer and its treatment and some of the therapies discussed here may involve considerable financial commitment. Caution may also need to be advised if the CAM potentially contains oestrogenic compounds which may explain the mechanism of action and which theoretically could compromise breast cancer survival. Pharmacological treatment is often recommended by health professionals for AIMSS, however in conclusion, there is limited published evidence for its use. Exercise showed benefit in a single RCT (Irwin et al., 2015) , but the other studies showed little evidence of benefit. Information from the meta-analysis is limited by inclusion of only two studies with opposing results. The evidence for acupuncture is not strong enough to recommend it for the treatment of AIMSS. Although the interventions generally appear tolerable with minimal adverse effects, the current level of evidence is low, and additional large RCTs with more rigorous control for contamination from other interventions are required to confirm some of the reported promising results.
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